Table 1.

Summary of inhibitory receptors in clinical trials.

Receptor	Binding Partners	Therapies under development	Clinical trials
LAG3	MHC II	IMP321 Relatlimab LAG525 TSR-033 REGN3767 MK-4280	IMP321: Vaccine adjuvant    With gemcitabine for pancreatic cancer    With paclitaxel in breast cancer    With pembrolizumab in HNSCC Relatlimab: With nivolumab in melanoma LAG525: With Spartalizumab in advanced solid tumors
TIM-3	Galectin-9 Ceacam1 HMGB1 Phosphatidylserine	MGB453 TSR-022 Sym023 BGBA425 RO7121661 ICAGN02390 LY3321367 BMS-986258	LY3321367: With and without anti-PD-L1 in advanced solid tumors MBG453: With spartalizumab in NSCLC and melanoma
TIGIT	CD155 CD112	BMS-986207 BGB-A1217 Tiragolumab AB154 ASP8374 MK-7684 COM701 LY3435151	Tiragolumab: With atezolizumab in NSCLC      With atezolizumab in advanced solid tumors
VISTA	Unknown	JNJ-61610588 (CI-8993) CA-170 W0180	CA170: In advanced solid tumors and lymphoma   In mesothelioma
NRP-1	Class 3 Semaphorins Growth factors (VEGF, TGF, HPF and others)	MNRP1685A ASP1948 CEND1	MNRP1685A: with bevacizumab, with or without paclitaxel in advanced solid tumors CEND1: with gemcitabine and nab-paclitaxel in pancreatic cancer